Adding Alzheimer's Risk Option, 23andMe Revives Questions on Utility of DTC Genomics

The "opt-in" model ensures that customers are aware of the risks and limitations of this potentially sensitive data, but some are questioning whether the direct-to-consumer model is the appropriate mechanism for delivering information on APOE status, even with additional precautions.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.